SUN PHARMA TO MARKET GLEEVEC'S GENERIC VERSION

The $2.2 billion anti-cancer drug Gleevec is about to face stiff competition from Indian shores. Mumbai-based Sun Pharma is among the first generic firms to have approached the US Food and Drug Administration to market a generic version in US market. India Business (http://timesofindia.indiatimes.com/articleshow/1927836.cms)